---
title: "Akero Therapeutics Reports Increased Q2 2025 Operating Expenses, No Revenue or Profit Data Provided"
description: "Akero Therapeutics Inc. reported its Q2 2025 financial results, revealing operating expenses of $80.9 million, up from $65.7 million in Q2 2024. The increase was driven by higher research and developm"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252215511.md"
published_at: "2025-08-08T11:15:17.000Z"
---

# Akero Therapeutics Reports Increased Q2 2025 Operating Expenses, No Revenue or Profit Data Provided

> Akero Therapeutics Inc. reported its Q2 2025 financial results, revealing operating expenses of $80.9 million, up from $65.7 million in Q2 2024. The increase was driven by higher research and development costs, primarily due to ongoing Phase 3 studies. The company holds $1,086.2 million in cash and equivalents, expected to fund operations until 2028. Significant updates include results from the Phase 2b SYMMETRY trial and presentations at the EASL Congress 2025, showcasing the anti-fibrotic activity of EFX and advancements in fibrosis detection methods.

Akero Therapeutics Inc. has released its financial results for the second quarter ending June 30, 2025. The company reported cash, cash equivalents, and short and long-term marketable securities amounting to $1,086.2 million. Akero expects these funds to support its current operating plan into 2028. Research and development expenses for the quarter were noted at $69.3 million, up from $55.3 million in the same period in 2024. This increase was primarily due to ongoing Phase 3 SYNCHRONY studies and the production of clinical supplies for Phase 3 and potential marketing applications, along with higher personnel costs. General and administrative expenses also rose to $11.6 million from $10.4 million in the previous year, driven by increased personnel and professional services expenses. The total operating expenses for the quarter were $80.9 million, compared to $65.7 million for the same period in 2024. Significant business updates include published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine and three presentations at the EASL Congress 2025. These presentations highlighted data showing statistically significant reversal of compensated cirrhosis (F4) due to MASH and confirmed the anti-fibrotic activity of EFX in patients with pre-cirrhotic (F2-F3) MASH. Additionally, AI-based analysis supported the treatment effect observed by conventional pathology scoring. A supporting poster suggested that qFibrosis® might detect fibrosis improvement earlier than conventional methods. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508763-en) on August 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [AKRO.US - Akero Therapeutics](https://longbridge.com/en/quote/AKRO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| ACROBiosystems 在 bioSeedin 的 JPM Spotlight 会议上推动创新，并战略性地支持全球合作伙伴关系的建立 | ACROBiosystems 参加了于 1 月 11 日举行的 BIOSeedin 冬季创新合作峰会，此次峰会在旧金山的 J.P. Morgan 2026 之前举行。此次活动以 “创新资产的全球匹配” 为主题，汇聚了跨国制药公司、投资者和生 | [Link](https://longbridge.com/en/news/275692064.md) |
| Rakovina Therapeutics 任命 Kim Oishi 为首席执行官和董事 | Rakovina Therapeutics Inc. 已任命 Kim Oishi 为首席执行官和董事。Dennis Brown 已辞去董事会职务，但将继续担任科学顾问委员会主席。Al DeLucrezia 也已辞去董事会职务，将继续担任顾问 | [Link](https://longbridge.com/en/news/273889407.md) |
| FDA 授予拜耳的 OpCT-001 用于治疗视网膜色素变性的孤儿药资格 | 拜耳公司和 BlueRock Therapeutics 宣布，美国食品药品监督管理局（FDA）已授予其研究性细胞疗法 OpCT-001 孤儿药资格，用于治疗视网膜色素变性。这种疗法源自诱导多能干细胞，目前正在进行针对主要光感受器疾病的 1/ | [Link](https://longbridge.com/en/news/273335268.md) |
| Aker BioMarine 第四季度调整后的息税折旧及摊销前利润（EBITDA）增长 66%，达到 1060 万美元 | Aker BioMarine ASA 报告了 2025 年第四季度的收入为 5520 万美元，同比增长 6%，调整后的 EBITDA 上升 66% 至 1060 万美元。2025 财年的收入达到 2.181 亿美元，同比增长 10%，调整后 | [Link](https://longbridge.com/en/news/275706260.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.